HUE036035T2 - Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra - Google Patents

Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra

Info

Publication number
HUE036035T2
HUE036035T2 HUE14812465A HUE14812465A HUE036035T2 HU E036035 T2 HUE036035 T2 HU E036035T2 HU E14812465 A HUE14812465 A HU E14812465A HU E14812465 A HUE14812465 A HU E14812465A HU E036035 T2 HUE036035 T2 HU E036035T2
Authority
HU
Hungary
Prior art keywords
kromon
dopamine
derivative
treatment
receptor antagonist
Prior art date
Application number
HUE14812465A
Other languages
English (en)
Hungarian (hu)
Inventor
Agnes Auclair
Paul Moser
Pierre Sokoloff
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of HUE036035T2 publication Critical patent/HUE036035T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14812465A 2013-12-13 2014-12-12 Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra HUE036035T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306726 2013-12-13

Publications (1)

Publication Number Publication Date
HUE036035T2 true HUE036035T2 (hu) 2018-06-28

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14812465A HUE036035T2 (hu) 2013-12-13 2014-12-12 Kromon-származék mint dopamin-D3 receptor antagonista autizmus spektrum betegség kezelésében történõ alkalmazásra

Country Status (29)

Country Link
US (1) US10028948B2 (enExample)
EP (1) EP3079688B1 (enExample)
JP (1) JP6419826B2 (enExample)
KR (1) KR102280530B1 (enExample)
CN (1) CN105792824B (enExample)
AU (1) AU2014363428B2 (enExample)
BR (1) BR112016012552A8 (enExample)
CA (1) CA2932791C (enExample)
CY (1) CY1119907T1 (enExample)
DK (1) DK3079688T3 (enExample)
ES (1) ES2657706T3 (enExample)
HR (1) HRP20180323T8 (enExample)
HU (1) HUE036035T2 (enExample)
IL (1) IL245996B (enExample)
LT (1) LT3079688T (enExample)
MA (1) MA39076A1 (enExample)
MX (1) MX372922B (enExample)
MY (1) MY172937A (enExample)
NO (1) NO3079688T3 (enExample)
NZ (1) NZ720868A (enExample)
PL (1) PL3079688T3 (enExample)
PT (1) PT3079688T (enExample)
RS (1) RS56931B1 (enExample)
RU (2) RU2019104946A (enExample)
SA (1) SA516371298B1 (enExample)
SI (1) SI3079688T1 (enExample)
TN (1) TN2016000213A1 (enExample)
UA (1) UA117271C2 (enExample)
WO (1) WO2015086836A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CA3152645A1 (en) * 2019-09-11 2021-03-18 Oxford BioDynamics PLC Diagnostic chromosome marker
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
FR2976179A1 (fr) * 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
ES2657706T3 (es) 2018-03-06
MA39076A1 (fr) 2017-05-31
AU2014363428A1 (en) 2016-06-23
JP6419826B2 (ja) 2018-11-07
BR112016012552A8 (pt) 2022-11-08
KR102280530B1 (ko) 2021-07-21
EP3079688A1 (en) 2016-10-19
HK1223563A1 (zh) 2017-08-04
PL3079688T3 (pl) 2018-05-30
RU2019104946A (ru) 2019-04-01
WO2015086836A1 (en) 2015-06-18
US10028948B2 (en) 2018-07-24
MX372922B (es) 2020-04-27
TN2016000213A1 (en) 2017-10-06
JP2016540000A (ja) 2016-12-22
IL245996A0 (en) 2016-07-31
RU2686110C1 (ru) 2019-04-24
RS56931B1 (sr) 2018-05-31
CN105792824B (zh) 2018-08-03
US20160303117A1 (en) 2016-10-20
IL245996B (en) 2018-11-29
LT3079688T (lt) 2018-02-12
SA516371298B1 (ar) 2018-06-07
NO3079688T3 (enExample) 2018-04-21
CN105792824A (zh) 2016-07-20
MX2016007612A (es) 2016-09-09
AU2014363428B2 (en) 2019-09-12
CA2932791C (en) 2021-11-09
HRP20180323T1 (hr) 2018-04-06
NZ720868A (en) 2022-04-29
CA2932791A1 (en) 2015-06-18
DK3079688T3 (da) 2018-01-29
SI3079688T1 (en) 2018-03-30
CY1119907T1 (el) 2018-06-27
PT3079688T (pt) 2018-02-28
UA117271C2 (uk) 2018-07-10
KR20160088886A (ko) 2016-07-26
MY172937A (en) 2019-12-16
HRP20180323T8 (hr) 2019-01-25
EP3079688B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
CY2023027I1 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
IL283032A (en) Preparations for oral administration of tofacitinib
IL246025B (en) Formulations for neoplasia vaccines
PL2919766T3 (pl) Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
DK2794626T6 (da) E-selectin-antagonistforbindelser
ITMI20131499A1 (it) Filtro per orinatoio
HUE049345T2 (hu) Nyújtott hatóanyag-leadású dózisformák JAK1 inhibitorhoz
DK3024468T3 (da) T-cellereceptorer
DK2890434T3 (da) Lægemiddeladministrationsanordning
DK2970389T3 (da) Farmaceutiske forbindelser
PL3124018T3 (pl) Doustne formulacje deferazyroksu
UA30221S (uk) Внутрішньоротовий пристрій
BR112016010669A2 (pt) composição desinfetante
EP2835693A4 (en) Image forming device
EP2750373A4 (en) Imaging device
IL245996A0 (en) A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder
PT3035941T (pt) Utilização de uma molécula de mir172 para reduzir a inflamação
UA30220S (uk) Внутрішньоротовий пристрій
EP3043648C0 (en) PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE
BR112016001395A2 (pt) forma de dosagem unitária oral sólida de metaxalona
ES1074561Y (es) Aparato intraoral anti-ronquido
TH1601003463A (th) อนุพันธ์โครโมนในฐานะแอนตะกอนิสต์ของโดพามีน d3 รีเซปเตอร์ สำหรับการใช้เพื่อการรักษากลุ่มโรคออทิสติก
UA30721S (uk) Міні-бункер для сіялки
DK2890435T3 (da) Lægemiddeladministrationsanordning
UA24793S (uk) Насос - дозатор для косметичних засобів